Kopran

Market Cap: Micro Cap
Industry: Pharmaceuticals & Drugs
ISIN: INE082A01010
NSEID: KOPRAN
BSEID: 524280

INR

189.10

14.65 (8.4%)

BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 4.52 lacs

{
  "main_header": {
    "sid": 568367,
    "name": "Kopran",
    "stock_name": "Kopran",
    "full_name": "Kopran Ltd",
    "name_url": "stocks-analysis/kopran",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "189.10",
    "chg": 14.65,
    "chgp": "8.4%",
    "dir": 1,
    "prev_price": "174.45",
    "mcapval": "913.08 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524280,
    "symbol": "KOPRAN",
    "ind_name": "Pharmaceuticals & Drugs",
    "ind_code": 4,
    "isin": "INE082A01010",
    "curr_date": "Apr 11, 12:53 PM",
    "curr_time": "00:09 AM",
    "bse_nse_vol": "4.52 lacs",
    "exc_status": "Active",
    "traded_date": "Apr 11, 2025",
    "traded_date_str": "2025 04 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://sandbox-www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/kopran-568367-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Kopran's Technical Outlook Shifts Amid Mixed Market Signals and Financial Challenges",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/kopran-receives-sell-upgrade-amid-declining-financial-performance-and-stock-volatility-1542464",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/Kopran_mojoScore_747199.png",
        "date": "2025-03-21 08:02:42",
        "description": "Kopran, a microcap in the Pharmaceuticals & Drugs sector, has experienced a recent evaluation adjustment reflecting changes in its technical outlook. Key metrics indicate a bearish sentiment, while the company's financial health remains strong despite challenges such as decreased institutional participation and recent negative results."
      },
      {
        "title": "Kopran Experiences Technical Trend Shifts Amidst Market Volatility and Historical Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/koprans-technical-trend-shifts-from-bearish-to-mildly-bearish-amid-stock-price-increase-1542537",
        "imagepath": "",
        "date": "2025-03-21 08:01:38",
        "description": "Kopran, a microcap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation revision reflecting its current market dynamics. The stock is currently priced at 181.90, showing a notable increase from the previous close of 175.15. Over the past year, Kopran has experienced significant volatility, with a 52-week high of 369.20 and a low of 157.00.\n\nIn terms of technical indicators, the weekly MACD remains bearish, while the monthly outlook is mildly bearish. The Relative Strength Index (RSI) shows no signals for both weekly and monthly assessments. Bollinger Bands indicate a mildly bearish trend on both timeframes, and moving averages are bearish on a daily basis. However, the KST presents a mildly bullish signal weekly, while remaining mildly bearish monthly. The On-Balance Volume (OBV) reflects a mildly bullish trend in both weekly and monthly evaluations.\n\nWhen comparing Kopran's ..."
      },
      {
        "title": "Kopran Faces Financial Struggles Amid Declining Stock Performance and Investor Interest",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kopran-ltd-hits-52-week-low-amid-ongoing-underperformance-in-pharmaceuticals-sector-1406525",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/Kopran_priceRelatedfactors_682062.png",
        "date": "2025-03-17 15:38:58",
        "description": "Kopran, a microcap pharmaceutical company, is nearing its 52-week low, reflecting a challenging performance with a significant decline over the past year. Recent financial metrics show slow growth in sales and profits, while institutional investor participation has decreased. However, the company maintains a low debt-to-EBITDA ratio, indicating some financial stability."
      },
      {
        "title": "Kopran Faces Significant Volatility Amid Declining Financial Performance and Investor Participation",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kopran-ltd-hits-52-week-low-amid-declining-financial-performance-and-stock-trends-1342267",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/Kopran_priceRelatedfactors_662855.png",
        "date": "2025-03-13 10:06:33",
        "description": "Kopran, a microcap in the Pharmaceuticals & Drugs sector, has faced notable volatility, reaching a new 52-week low. The company reported disappointing growth in net sales and operating profit over five years, alongside recent declines in quarterly profits. Institutional investor participation has decreased, though Kopran maintains a low debt-to-EBITDA ratio."
      },
      {
        "title": "Kopran Faces Continued Volatility Amid Broader Market Decline and Weak Growth Prospects",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kopran-ltd-hits-52-week-low-amid-ongoing-decline-and-poor-financial-performance-1311570",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/Kopran_priceRelatedfactors_659271.png",
        "date": "2025-03-12 11:37:34",
        "description": "Kopran, a microcap pharmaceutical company, has hit a new 52-week low amid ongoing volatility and underperformance in its sector. The stock's technical outlook remains bearish, with declining sales and profit figures. Despite challenges, the company shows some financial stability with a low debt-to-EBITDA ratio and a reasonable return on capital employed."
      },
      {
        "title": "Kopran Faces Significant Stock Volatility Amidst Ongoing Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kopran-ltd-hits-52-week-low-as-stock-declines-34-48-over-past-year-1171686",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/Kopran_priceRelatedfactors_561880.png",
        "date": "2025-03-03 10:06:41",
        "description": "Kopran, a microcap in the Pharmaceuticals & Drugs sector, has shown significant stock volatility, nearing its 52-week low. Over the past week, it has declined notably, underperforming its sector. The stock is currently trading below all major moving averages, reflecting ongoing challenges in a competitive market."
      },
      {
        "title": "Kopran Hits New Low Amid Ongoing Downward Trend in Pharmaceuticals Sector",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kopran-ltd-hits-new-52-week-low-amid-continued-stock-decline-1039875",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/Kopran_priceRelatedfactors_450916.png",
        "date": "2025-02-17 09:38:26",
        "description": "Kopran, a microcap in the Pharmaceuticals & Drugs sector, has reached a new 52-week low, continuing a downward trend with a 6.93% decline over three days. Its one-year performance shows a significant drop of 39.43%, contrasting with the Sensex's gains, indicating ongoing challenges in the market."
      },
      {
        "title": "Kopran Hits 52-Week Low Amidst High Volatility and Persistent Downward Trend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kopran-ltd-hits-52-week-low-of-rs-162-4-amid-35-66-annual-decline-987012",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/Kopran_priceRelatedfactors_413035.png",
        "date": "2025-02-12 09:36:35",
        "description": "Kopran, a microcap in the Pharmaceuticals & Drugs sector, has reached a new 52-week low amid significant volatility, with an intraday decline of 5.5%. The stock has faced consecutive losses over four days, trailing its sector and showing a 35.66% decline over the past year."
      },
      {
        "title": "Kopran Reports Q3 FY24-25 Financial Results Amid Ongoing Challenges and Stable Evaluation",
        "link": "https://www.marketsmojo.com/news/result-analysis/kopran-reports-negative-financial-results-for-q3-of-fiscal-year-2024-25-961772",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/Kopran_quaterlyResult_410255.png",
        "date": "2025-02-11 18:17:34",
        "description": "Kopran has announced its financial results for the quarter ending February 2025, revealing a challenging performance for Q3 FY24-25. Despite these difficulties, the company's evaluation score has remained stable over the past three months, indicating no significant changes in its overall financial assessment. Stakeholders should monitor future developments closely."
      }
    ],
    "total": 83,
    "sid": "568367",
    "stock_news_url": "https://sandbox-www.marketsmojo.com/news/kopran-568367"
  },
  "announcements": [
    {
      "caption": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A",
      "datetime": "09-Apr-2025",
      "details": "<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Kopran Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230MH1958PLC011078</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>BBB+</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>CRISIL LTD.</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Sunil Sodhani <br/> Designation: Company Secretary and Compliance Officer <br/> EmailId: sunil@kopran.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Basant Kumar Soni <br/> Designation: Chief Financial Officer <br/> EmailId: bksoni@kopran.com</div> </div> <div> <br/> Date: 09/04/2025<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "08-Apr-2025",
      "details": "Compliance Certificate under Reg.74(5) of SEBI (DP) Regulation 2018 for the Quarter ended March 31 2025",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
      "datetime": "27-Mar-2025",
      "details": "Transcript and audio recording of Investors Meet held on March 25 2025.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Kopran Ltd has declared <strong>30%</strong> dividend, ex-date: 02 Sep 24",
          "dt": "2024-09-02",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Kopran's Technical Outlook Shifts Amid Mixed Market Signals and Financial Challenges

2025-03-21 08:02:42

Kopran, a microcap in the Pharmaceuticals & Drugs sector, has experienced a recent evaluation adjustment reflecting changes in its technical outlook. Key metrics indicate a bearish sentiment, while the company's financial health remains strong despite challenges such as decreased institutional participation and recent negative results.

Kopran Experiences Technical Trend Shifts Amidst Market Volatility and Historical Performance

2025-03-21 08:01:38

Kopran, a microcap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation revision reflecting its current market dynamics. The stock is currently priced at 181.90, showing a notable increase from the previous close of 175.15. Over the past year, Kopran has experienced significant volatility, with a 52-week high of 369.20 and a low of 157.00. In terms of technical indicators, the weekly MACD remains bearish, while the monthly outlook is mildly bearish. The Relative Strength Index (RSI) shows no signals for both weekly and monthly assessments. Bollinger Bands indicate a mildly bearish trend on both timeframes, and moving averages are bearish on a daily basis. However, the KST presents a mildly bullish signal weekly, while remaining mildly bearish monthly. The On-Balance Volume (OBV) reflects a mildly bullish trend in both weekly and monthly evaluations. When comparing Kopran's ...

Kopran Faces Financial Struggles Amid Declining Stock Performance and Investor Interest

2025-03-17 15:38:58

Kopran, a microcap pharmaceutical company, is nearing its 52-week low, reflecting a challenging performance with a significant decline over the past year. Recent financial metrics show slow growth in sales and profits, while institutional investor participation has decreased. However, the company maintains a low debt-to-EBITDA ratio, indicating some financial stability.

Kopran Faces Significant Volatility Amid Declining Financial Performance and Investor Participation

2025-03-13 10:06:33

Kopran, a microcap in the Pharmaceuticals & Drugs sector, has faced notable volatility, reaching a new 52-week low. The company reported disappointing growth in net sales and operating profit over five years, alongside recent declines in quarterly profits. Institutional investor participation has decreased, though Kopran maintains a low debt-to-EBITDA ratio.

Kopran Faces Continued Volatility Amid Broader Market Decline and Weak Growth Prospects

2025-03-12 11:37:34

Kopran, a microcap pharmaceutical company, has hit a new 52-week low amid ongoing volatility and underperformance in its sector. The stock's technical outlook remains bearish, with declining sales and profit figures. Despite challenges, the company shows some financial stability with a low debt-to-EBITDA ratio and a reasonable return on capital employed.

Kopran Faces Significant Stock Volatility Amidst Ongoing Market Challenges

2025-03-03 10:06:41

Kopran, a microcap in the Pharmaceuticals & Drugs sector, has shown significant stock volatility, nearing its 52-week low. Over the past week, it has declined notably, underperforming its sector. The stock is currently trading below all major moving averages, reflecting ongoing challenges in a competitive market.

Kopran Hits New Low Amid Ongoing Downward Trend in Pharmaceuticals Sector

2025-02-17 09:38:26

Kopran, a microcap in the Pharmaceuticals & Drugs sector, has reached a new 52-week low, continuing a downward trend with a 6.93% decline over three days. Its one-year performance shows a significant drop of 39.43%, contrasting with the Sensex's gains, indicating ongoing challenges in the market.

Kopran Hits 52-Week Low Amidst High Volatility and Persistent Downward Trend

2025-02-12 09:36:35

Kopran, a microcap in the Pharmaceuticals & Drugs sector, has reached a new 52-week low amid significant volatility, with an intraday decline of 5.5%. The stock has faced consecutive losses over four days, trailing its sector and showing a 35.66% decline over the past year.

Kopran Reports Q3 FY24-25 Financial Results Amid Ongoing Challenges and Stable Evaluation

2025-02-11 18:17:34

Kopran has announced its financial results for the quarter ending February 2025, revealing a challenging performance for Q3 FY24-25. Despite these difficulties, the company's evaluation score has remained stable over the past three months, indicating no significant changes in its overall financial assessment. Stakeholders should monitor future developments closely.

View All News

Announcement

Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

09-Apr-2025 | Source : BSE

Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No.	Particulars	Details
1	Name of Company	Kopran Ltd
2	CIN NO.	L24230MH1958PLC011078
3	Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)	0.00
4	Highest Credit Rating during the previous FY	BBB+
4a	Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)	CRISIL LTD.
5	Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework	BSE

We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No

Name of the Company Secretary: Sunil Sodhani
Designation: Company Secretary and Compliance Officer
EmailId: sunil@kopran.com

Name of the Chief Financial Officer: Basant Kumar Soni
Designation: Chief Financial Officer
EmailId: bksoni@kopran.com

Date: 09/04/2025

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.